2026-05-14
COA Report Card: Is your vendor transparent?What to look for in a Certificate of Analysis, what red flags to ignore, and why most vendors don't pass the test.
read →journal
2026-05-13
The ground is shifting for compounding pharmaciesThe rules for compounded semaglutide and tirzepatide are tightening. What it means for your next prescription.
read →2026-05-12
GLP-1 Agonists Are Changing OBGYN Practice. Here's What the Paper Says.A 2026 clinical review outlines what obstetricians need to know about GLP-1 drugs in PCOS, pregnancy exposure, contraception, and surgery — and what's still missing.
read →2026-05-12
Semaglutide taken on scan day ruins PET/CT imaging qualityA case report shows same-day semaglutide injection causes muscle uptake that obscures cancer lesions on PET/CT scans, resolved after six days off the drug.
read →2026-05-12
Tirzepatide beats dulaglutide on kidney outcomes in type 2 diabetics with heart diseaseSURPASS-CVOT shows tirzepatide reduced major kidney events 23% versus dulaglutide over four years in diabetics with cardiovascular disease, driven by less protein spillage and slower decline.
read →2026-05-12
What we know about retatrutide (and what we don't)The compound everyone is buying before the FDA finishes. What the data says. What's missing.
read →2026-05-11
Why PACO Peptide existsThe first entry. What we're building and why.
read →Want Bukowski to explain this in your context?
Read the study. Then ask what it means for your journey, symptoms, and questions.
try Bukowski ↗